Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
116 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Gouty Arthritis (Gout) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Gouty Arthritis (Gout) - Pipeline Review, H1 2016', provides an overview of the Gouty Arthritis (Gout) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout) - The report reviews pipeline therapeutics for Gouty Arthritis (Gout) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Gouty Arthritis (Gout) therapeutics and enlists all their major and minor projects - The report assesses Gouty Arthritis (Gout) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Gouty Arthritis (Gout) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Gouty Arthritis (Gout) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Gouty Arthritis (Gout) Overview 10 Therapeutics Development 11 Pipeline Products for Gouty Arthritis (Gout) - Overview 11 Pipeline Products for Gouty Arthritis (Gout) - Comparative Analysis 12 Gouty Arthritis (Gout) - Therapeutics under Development by Companies 13 Gouty Arthritis (Gout) - Therapeutics under Investigation by Universities/Institutes 16 Gouty Arthritis (Gout) - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Gouty Arthritis (Gout) - Products under Development by Companies 21 Gouty Arthritis (Gout) - Products under Investigation by Universities/Institutes 23 Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development 24 AstraZeneca Plc 24 Celtaxsys, Inc. 25 CymaBay Therapeutics, Inc. 26 Delenex Therapeutics AG 27 Immune Response BioPharma, Inc. 28 IOmet Pharma 29 JW Pharmaceutical Corporation 30 LG Life Science LTD. 31 Monosol Rx, LLC 32 Nimbus Therapeutics, LLC 33 Opsona Therapeutics Limited 34 Polaris Pharmaceuticals, Inc. 35 ProteoThera, Inc. 36 Swedish Orphan Biovitrum AB 37 Takeda Pharmaceutical Company Limited 38 Teijin Pharma Limited 39 TWi Pharmaceuticals, Inc. 40 Wellstat Therapeutics Corporation 41 Gouty Arthritis (Gout) - Therapeutics Assessment 42 Assessment by Monotherapy Products 42 Assessment by Target 43 Assessment by Mechanism of Action 45 Assessment by Route of Administration 47 Assessment by Molecule Type 49 Drug Profiles 51 acebilustat - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 anakinra (recombinant) - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 APP-112 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 arhalofenate - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 AXIBU-03 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 colchicine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 diacerein - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 DLX-2323 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 DLX-2681 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 febuxostat - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 febuxostat XR - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 IR-888 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 LC-350189 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation and Neurodegenerative Diseases - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 ND-2110 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 ND-2158 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 ND-346 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 pegadricase - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 PRT-1000 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Recombinant Enzyme for Gout and Tumor Lysis Syndrome - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 REV-002 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 RLBN-1001 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 RLBN-2020 Series - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 RLBN-3010 Series - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Small Molecule Inflammasome Modulator Programme - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Small Molecules to Inhibit GLUT9 for Gout - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 TMX-049 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 URC-102 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 uriSHELS - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 verinurad - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 WT-2107 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 XEN-102 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 XEN-104 - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 Gouty Arthritis (Gout) - Recent Pipeline Updates 93 Gouty Arthritis (Gout) - Dormant Projects 104 Gouty Arthritis (Gout) - Discontinued Products 106 Gouty Arthritis (Gout) - Product Development Milestones 107 Featured News & Press Releases 107 Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra) 107 Mar 28, 2016: CymaBay Therapeutics Announces Acceptance of Arhalofenate Phase 2b Gout Study Manuscript in Arthritis and Rheumatology 107 Mar 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra) 108 Jan 20, 2016: CymaBay Therapeutics Announces Successful Completion of End-of-Phase 2 Discussions With FDA for Arhalofenate 109 Dec 24, 2015: TWi Biotechnology Reports Positive Interim Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients 110 Dec 23, 2015: Selecta Biosciences Announces Dosing of First Patient in Phase 1b Clinical Trial of SEL-212, Designed to be the First Non-Immunogenic Biologic Treatment for Gout 110 Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6 - 11 111 Oct 19, 2015: MonoSol Rx Leadership Presents Data Supporting PharmFilm Technology Effective for Oral Peptide Delivery 112 Sep 30, 2015: Revive Therapeutics Announces Positive Interim Results From Phase 2a Study of REV-002 in the Treatment of Acute Gout Flares 113 Aug 06, 2015: CymaBay Strengthens the Intellectual Property of Arhalofenate With Issuance of Two New Patents 114 Appendix 115 Methodology 115 Coverage 115 Secondary Research 115 Primary Research 115 Expert Panel Validation 115 Contact Us 115 Disclaimer 116
List of Tables
Number of Products under Development for Gouty Arthritis (Gout), H1 2016 11 Number of Products under Development for Gouty Arthritis (Gout) - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Development by Companies, H1 2016 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H1 2016 16 Comparative Analysis by Late Stage Development, H1 2016 17 Comparative Analysis by Clinical Stage Development, H1 2016 18 Comparative Analysis by Early Stage Development, H1 2016 19 Comparative Analysis by Unknown Stage Development, H1 2016 20 Products under Development by Companies, H1 2016 21 Products under Development by Companies, H1 2016 (Contd..1) 22 Products under Investigation by Universities/Institutes, H1 2016 23 Gouty Arthritis (Gout) - Pipeline by AstraZeneca Plc, H1 2016 24 Gouty Arthritis (Gout) - Pipeline by Celtaxsys, Inc., H1 2016 25 Gouty Arthritis (Gout) - Pipeline by CymaBay Therapeutics, Inc., H1 2016 26 Gouty Arthritis (Gout) - Pipeline by Delenex Therapeutics AG, H1 2016 27 Gouty Arthritis (Gout) - Pipeline by Immune Response BioPharma, Inc., H1 2016 28 Gouty Arthritis (Gout) - Pipeline by IOmet Pharma, H1 2016 29 Gouty Arthritis (Gout) - Pipeline by JW Pharmaceutical Corporation, H1 2016 30 Gouty Arthritis (Gout) - Pipeline by LG Life Science LTD., H1 2016 31 Gouty Arthritis (Gout) - Pipeline by Monosol Rx, LLC, H1 2016 32 Gouty Arthritis (Gout) - Pipeline by Nimbus Therapeutics, LLC, H1 2016 33 Gouty Arthritis (Gout) - Pipeline by Opsona Therapeutics Limited, H1 2016 34 Gouty Arthritis (Gout) - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016 35 Gouty Arthritis (Gout) - Pipeline by ProteoThera, Inc., H1 2016 36 Gouty Arthritis (Gout) - Pipeline by Swedish Orphan Biovitrum AB, H1 2016 37 Gouty Arthritis (Gout) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 38 Gouty Arthritis (Gout) - Pipeline by Teijin Pharma Limited, H1 2016 39 Gouty Arthritis (Gout) - Pipeline by TWi Pharmaceuticals, Inc., H1 2016 40 Gouty Arthritis (Gout) - Pipeline by Wellstat Therapeutics Corporation, H1 2016 41 Assessment by Monotherapy Products, H1 2016 42 Number of Products by Stage and Target, H1 2016 44 Number of Products by Stage and Mechanism of Action, H1 2016 46 Number of Products by Stage and Route of Administration, H1 2016 48 Number of Products by Stage and Molecule Type, H1 2016 50 Gouty Arthritis (Gout) Therapeutics - Recent Pipeline Updates, H1 2016 93 Gouty Arthritis (Gout) - Dormant Projects, H1 2016 104 Gouty Arthritis (Gout) - Dormant Projects (Contd..1), H1 2016 105 Gouty Arthritis (Gout) - Discontinued Products, H1 2016 106
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
